Pharmacological effects of the targeted drug capmatinib

Capmatinib is a targeted therapy specifically designed to inhibit the activity of the MET receptor tyrosine kinase. MET is a gene encoding hepatocyte growth factor receptor. Its activation is closely related to the occurrence and development of various cancers, especially in non-small cell lung cancer (NSCLC). MET gene mutation or amplification is a driving factor in cancer progression. Capmatinib specifically inhibits the signaling pathway of the MET receptor, slows down the proliferation of tumor cells, inhibits tumor metastasis, and thereby delays the progression of the disease.

METexon14 skipping mutation is one of the common driver mutations in patients with non-small cell lung cancer, which usually leads to abnormal activation of the MET signaling pathway. Capmatinib is specifically approved to treat patients with this mutation. By blocking the signaling caused by this mutation, capmatinib can effectively inhibit the excessive activation of MET, reduce tumor growth, and improve the clinical prognosis of patients.

A distinctive feature of capmatinib is its high selectivity. It has a relatively strong selective inhibitory effect onMETreceptors, but has less effect on other receptors. Capmatinib's targeting properties allow it to cause less damage to healthy cells than many traditional chemotherapy drugs, thereby significantly reducing treatment-induced side effects. This high selectivity is one of its advantages as a treatment for MET mutant cancers.

Capmatinib can not only be used alone, but can also be used in combination with other targeted drugs or chemotherapy drugs to enhance its efficacy. For example, in patients with MET-mutated non-small cell lung cancer, capmatinib was able to achieve more significant tumor shrinkage when combined with other drugs. Combination therapy strategies can cooperate with each other through different mechanisms to further inhibit tumor growth and metastasis and improve patient survival rates.

Clinical studies have shown that capmatinib can significantly improve progression-free survival (PFS) and overall survival (OS) in patients with non-small cell lung cancer with skipping mutations in METExon 14). In a pivotal clinical trial, capmatinib showed superior efficacy to traditional chemotherapy drugs, particularly in patients who had failed other treatments. The pharmacological properties of capmatinib make it the preferred targeted therapy for the treatment of MET-driven lung cancer.

xa0

Reference materials

FDA Capmatinib Approval Information -

https://www.fda.gov/drugs/drug-approvals-and-databases/tabrecta-capmatinib